A team composed of Dr. Theodore Schreiber, Dr. Cindy Grines, Dr. Mahir Elder, Dr. Amir Kaki and Dr. Tamam Mohamad implanted a patient on July 11, 2016 with the world's first FDA-approved dissolving heart stent.

The Absorb bioresorbable vascular scaffold, manufactured by Abbott, is an advance in the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide despite decades of therapeutic advances.

While stents are traditionally made of metal, the Absorb™ stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb™ disappears in about three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants.

“The benefit of a bioresorbable stent comes from not implanting a permanent metal prosthesis,” explained Dr. Kaki, medical director of the Cardiac Catheterization Laboratories at DMC Heart Hospital. “After it has dissolved, the patient’s artery is restored to a natural state.”

DMC Heart Hospital President Dr. Theodore Schreiber stressed the forward-thinking that led to providing this innovation at DMC. “Our goal is to provide next-level care in every aspect – technically, clinically, and personally. This new technology is an excellent example of our ‘never settle for the status quo’ mindset.”

To ensure optimal patient selection and implant technique, DMC Heart Hospital’s interventional cardiology team underwent extensive training on the new device.

Detroit Medical Center includes DMC Children’s Hospital of Michigan, DMC Detroit Receiving Hospital, DMC Harper University Hospital, DMC Heart Hospital, DMC Huron Valley-Sinai Hospital, DMC Hutzel Women’s Hospital, DMC Rehabilitation Institute of Michigan, and DMC Sinai-Grace Hospital.

Detroit Medical Center is a leading regional healthcare system with a mission of excellence in clinical care, research and medical education.